{"a":[{"_":"Tavneos trial flagged for 'serious breaches' of protocol as EU regulators dissect market withdrawal decision","$":{"href":"/pharma/tavneos-pivotal-trial-flagged-serious-breaches-protocol-eu-regulators-dissect-market","hreflang":"en"}}]}
RegulatoryrejectedTavneosNegative
AI Analysis
Summary
The EU formally reversed marketing authorization for Tavneos, a complement inhibitor for rare disease treatment, citing serious protocol breaches identified in the pivotal trial data backing the drug's approval.
Outcome Details
EU marketing authorization formally reversed; pivotal trial flagged for serious protocol breaches
Importance:8/10
Sentiment:
-0.90
regulatory_actionmarket_withdrawalprotocol_violationscomplement_inhibitorrare_disease
Read the original article
Published by FiercePharma on August 14, 2026 10:45 AM